Anti-vascular endothelial growth factor (VEGF) monoclonal antibodies (mAbs) and small-molecule tyrosine kinase inhibitors (TKIs) are agents that block VEGF signalling by inactivating VEGF or VEGF receptors (VEGFR), respectively, thereby exerting anti-angiogenic effects within the tumour microenvironment [3]. Here, VEGFA is linked to neoplasm.